UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Phase 1 Completed
18 enrolled
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Phase 1 Completed
32 enrolled 12 charts
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase 2 Completed
77 enrolled 10 charts
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
210 enrolled 15 charts
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase 3 Completed
174 enrolled 12 charts
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Phase 1 Completed
41 enrolled
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
18 enrolled
EMN-alloRIC
Phase 1/2 Completed
49 enrolled
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Phase 2 Completed
32 enrolled
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
Phase 1 Completed
15 enrolled
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
Phase 2 Completed
32 enrolled 24 charts
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Completed
25 enrolled
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
Phase 1 Completed
25 enrolled
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
Phase 1 Completed
18 enrolled
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Phase 1/2 Completed